Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Technical Presentation (November 2021)

9 slides from Sorrento Therapeutics's technical presentation, Nov 29, 2021

  1. Slide 1: About Abivertinib

    About Abivertinib : · Abivertinib is a novel dual target, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). · Abivertinib is a third-generation epidermal growth factor receptor (EGFR

  2. Slide 2: Abivertinib Targets Bruton's Tyrosine Kinase (BTK)

    · Abivertinib Targets Bruton's Tyrosine Kinase (BTK) Figure 2. BTK Signaling Transduction Pathways in Regulation of Malignant B Lymphocyte Proliferation and Cytokine Expression

  3. Slide 3: BTK signaling pathway in B cells

    B cell antigen neceptor: Extracellularspace ws RAF ——." Nucleus SN ‘Transcription

  4. Slide 4: Slide 4

  5. Slide 5: Response to Abivertinib by dose

    The color key indicates the response to 300 mg BID of Abivertinib. Abbreviation: CR, complete response; NE: not evaluable; PD, progressive disease; PR, partial response; SD, stable disease

  6. Slide 6: Phase 1 study in R/R B-cell lymphoma

    § A Phase 1 study designed to determine the recommended Phase 2 dose (RP2D) of Abivertinib in patients with pre-treated R/R B-cell lymphoma (part 1) and to evaluate the safety and preliminary efficacy in patients with selected disease (part 2) was completed. Abivertinib has been investigated in an o

  7. Slide 7: Abivertinib in lupus-prone mouse models

    A and B : BXSB mice (n=7) were treated with Abivertinib (50 mg/kg PO, BID) or vehicle. Disease progression was monitored A) weekly by serologic analysis for anti-dsDNA and anti-nuclear (ANA) autoantibodies and by proteinuria. B) After 21 weeks of treatment, spleen and lymph node weights were examine

  8. Slide 8: Abivertinib in EAE mouse model

    C57BL/6 mice were pretreated with 100mg/kg (n = 10), 200mg/kg (n = 10), 300mg/kg Abivertinib (n = 10) or vehicle control (n=10) daily by oral gavage beginning 7 days prior to the MOG immunization. Clinical EAE scores were assessed daily and body weight was measured once per week. Data represent mean

  9. Slide 9: Abivertinib in human PBMC engrafted NSG mice

    Immunodeficient NSG recipients were engrafted with human PBMC at week 0. Groups (n=10) were either given daily oral gavage of vehicle, or Abivertinib 50mg/kg (BID) beginning one week prior to the PBMC transplantation and continued for 13 weeks. Mice were monitored for survival (A) and body weight (B

Sorrento Therapeutics — Technical Presentation (November 2021) on 6ix